Report cover image

Global Intravenous Immunoglobulin(IVIg) Therapy Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 200 Pages
SKU # APRC20359662

Description

Summary

According to APO Research, the global Intravenous Immunoglobulin(IVIg) Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Intravenous Immunoglobulin(IVIg) Therapy market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Intravenous Immunoglobulin(IVIg) Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Intravenous Immunoglobulin(IVIg) Therapy market include TEIJIN LIMITED, Baxter, Biotest, Boya-Bio, CNBG, CSL Plasma, Grifols, Kamada and Kedrion, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Intravenous Immunoglobulin(IVIg) Therapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Intravenous Immunoglobulin(IVIg) Therapy, also provides the sales of main regions and countries. Of the upcoming market potential for Intravenous Immunoglobulin(IVIg) Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Intravenous Immunoglobulin(IVIg) Therapy sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Intravenous Immunoglobulin(IVIg) Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Intravenous Immunoglobulin(IVIg) Therapy sales, projected growth trends, production technology, application and end-user industry.

Intravenous Immunoglobulin(IVIg) Therapy Segment by Company

TEIJIN LIMITED
Baxter
Biotest
Boya-Bio
CNBG
CSL Plasma
Grifols
Kamada
Kedrion
LFB Group
Nanyue Biopharming
Octapharma
Sinopharm
Beijing Tiantan Biological Products
Guangdong Shuagnlin Bio-pharmacy
Hualan Bio
Shanghai RAAS
Weiguang Biological
Taibang Biologic Group
Takeda
Intravenous Immunoglobulin(IVIg) Therapy Segment by Type

5g/100ml
2.5g/50ml
1g/20ml
10g/200ml
1.25g/25ml
Others
Intravenous Immunoglobulin(IVIg) Therapy Segment by Application

Autoimmune Disease
Immunodeficiency
Acute Infection
Others
Intravenous Immunoglobulin(IVIg) Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Intravenous Immunoglobulin(IVIg) Therapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Intravenous Immunoglobulin(IVIg) Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Intravenous Immunoglobulin(IVIg) Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Intravenous Immunoglobulin(IVIg) Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin(IVIg) Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin(IVIg) Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin(IVIg) Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous Immunoglobulin(IVIg) Therapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intravenous Immunoglobulin(IVIg) Therapy industry.
Chapter 3: Detailed analysis of Intravenous Immunoglobulin(IVIg) Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Intravenous Immunoglobulin(IVIg) Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Intravenous Immunoglobulin(IVIg) Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

200 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
1.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume (2020-2031)
1.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Intravenous Immunoglobulin(IVIg) Therapy Market Dynamics
2.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Trends
2.2 Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers
2.3 Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges
2.4 Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints
3 Intravenous Immunoglobulin(IVIg) Therapy Market by Company
3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Company Revenue Ranking in 2024
3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Company (2020-2025)
3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Company (2020-2025)
3.4 Global Intravenous Immunoglobulin(IVIg) Therapy Average Price by Company (2020-2025)
3.5 Global Intravenous Immunoglobulin(IVIg) Therapy Company Ranking (2023-2025)
3.6 Global Intravenous Immunoglobulin(IVIg) Therapy Company Manufacturing Base and Headquarters
3.7 Global Intravenous Immunoglobulin(IVIg) Therapy Company Product Type and Application
3.8 Global Intravenous Immunoglobulin(IVIg) Therapy Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Intravenous Immunoglobulin(IVIg) Therapy Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Intravenous Immunoglobulin(IVIg) Therapy Market by Type
4.1 Intravenous Immunoglobulin(IVIg) Therapy Type Introduction
4.1.1 5g/100ml
4.1.2 2.5g/50ml
4.1.3 1g/20ml
4.1.4 10g/200ml
4.1.5 1.25g/25ml
4.1.6 Others
4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type
4.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2020-2031)
4.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Type (2020-2031)
4.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type
4.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2020-2031)
4.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type (2020-2031)
5 Intravenous Immunoglobulin(IVIg) Therapy Market by Application
5.1 Intravenous Immunoglobulin(IVIg) Therapy Application Introduction
5.1.1 Autoimmune Disease
5.1.2 Immunodeficiency
5.1.3 Acute Infection
5.1.4 Others
5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application
5.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2020-2031)
5.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Application (2020-2031)
5.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application
5.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2020-2031)
5.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application (2020-2031)
6 Intravenous Immunoglobulin(IVIg) Therapy Regional Sales and Value Analysis
6.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2020-2031)
6.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2020-2025
6.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2026-2031)
6.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2020-2031)
6.4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region: 2020-2025
6.4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2026-2031)
6.5 Global Intravenous Immunoglobulin(IVIg) Therapy Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
6.6.2 North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
6.7.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
6.8.2 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
6.9.2 South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2020-2031)
6.10.2 Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2024 VS 2031
7 Intravenous Immunoglobulin(IVIg) Therapy Country-level Sales and Value Analysis
7.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2020-2031)
7.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2020-2025)
7.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2026-2031)
7.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2020-2031)
7.4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2020-2025)
7.4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.5.2 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.6.2 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.8.2 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.9.2 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.9.3 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.11.2 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.12.2 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.13.2 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.16.2 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.16.3 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.17.2 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.19.2 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.19.3 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.20.2 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.24.2 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.26.2 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.28.2 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.29.2 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.31.2 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 TEIJIN LIMITED
8.1.1 TEIJIN LIMITED Comapny Information
8.1.2 TEIJIN LIMITED Business Overview
8.1.3 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.1.4 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.1.5 TEIJIN LIMITED Recent Developments
8.2 Baxter
8.2.1 Baxter Comapny Information
8.2.2 Baxter Business Overview
8.2.3 Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.2.4 Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.2.5 Baxter Recent Developments
8.3 Biotest
8.3.1 Biotest Comapny Information
8.3.2 Biotest Business Overview
8.3.3 Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.3.4 Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.3.5 Biotest Recent Developments
8.4 Boya-Bio
8.4.1 Boya-Bio Comapny Information
8.4.2 Boya-Bio Business Overview
8.4.3 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.4.4 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.4.5 Boya-Bio Recent Developments
8.5 CNBG
8.5.1 CNBG Comapny Information
8.5.2 CNBG Business Overview
8.5.3 CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.5.4 CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.5.5 CNBG Recent Developments
8.6 CSL Plasma
8.6.1 CSL Plasma Comapny Information
8.6.2 CSL Plasma Business Overview
8.6.3 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.6.4 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.6.5 CSL Plasma Recent Developments
8.7 Grifols
8.7.1 Grifols Comapny Information
8.7.2 Grifols Business Overview
8.7.3 Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.7.4 Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.7.5 Grifols Recent Developments
8.8 Kamada
8.8.1 Kamada Comapny Information
8.8.2 Kamada Business Overview
8.8.3 Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.8.4 Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.8.5 Kamada Recent Developments
8.9 Kedrion
8.9.1 Kedrion Comapny Information
8.9.2 Kedrion Business Overview
8.9.3 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.9.4 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.9.5 Kedrion Recent Developments
8.10 LFB Group
8.10.1 LFB Group Comapny Information
8.10.2 LFB Group Business Overview
8.10.3 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.10.4 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.10.5 LFB Group Recent Developments
8.11 Nanyue Biopharming
8.11.1 Nanyue Biopharming Comapny Information
8.11.2 Nanyue Biopharming Business Overview
8.11.3 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.11.4 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.11.5 Nanyue Biopharming Recent Developments
8.12 Octapharma
8.12.1 Octapharma Comapny Information
8.12.2 Octapharma Business Overview
8.12.3 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.12.4 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.12.5 Octapharma Recent Developments
8.13 Sinopharm
8.13.1 Sinopharm Comapny Information
8.13.2 Sinopharm Business Overview
8.13.3 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.13.4 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.13.5 Sinopharm Recent Developments
8.14 Beijing Tiantan Biological Products
8.14.1 Beijing Tiantan Biological Products Comapny Information
8.14.2 Beijing Tiantan Biological Products Business Overview
8.14.3 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.14.4 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.14.5 Beijing Tiantan Biological Products Recent Developments
8.15 Guangdong Shuagnlin Bio-pharmacy
8.15.1 Guangdong Shuagnlin Bio-pharmacy Comapny Information
8.15.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
8.15.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.15.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.15.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
8.16 Hualan Bio
8.16.1 Hualan Bio Comapny Information
8.16.2 Hualan Bio Business Overview
8.16.3 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.16.4 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.16.5 Hualan Bio Recent Developments
8.17 Shanghai RAAS
8.17.1 Shanghai RAAS Comapny Information
8.17.2 Shanghai RAAS Business Overview
8.17.3 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.17.4 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.17.5 Shanghai RAAS Recent Developments
8.18 Weiguang Biological
8.18.1 Weiguang Biological Comapny Information
8.18.2 Weiguang Biological Business Overview
8.18.3 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.18.4 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.18.5 Weiguang Biological Recent Developments
8.19 Taibang Biologic Group
8.19.1 Taibang Biologic Group Comapny Information
8.19.2 Taibang Biologic Group Business Overview
8.19.3 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.19.4 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.19.5 Taibang Biologic Group Recent Developments
8.20 Takeda
8.20.1 Takeda Comapny Information
8.20.2 Takeda Business Overview
8.20.3 Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2020-2025)
8.20.4 Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
8.20.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Intravenous Immunoglobulin(IVIg) Therapy Value Chain Analysis
9.1.1 Intravenous Immunoglobulin(IVIg) Therapy Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Intravenous Immunoglobulin(IVIg) Therapy Sales Mode & Process
9.2 Intravenous Immunoglobulin(IVIg) Therapy Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Intravenous Immunoglobulin(IVIg) Therapy Distributors
9.2.3 Intravenous Immunoglobulin(IVIg) Therapy Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.